Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Author Profile and Citation Impact

OpenAlex indexes Youri Glupczynski (ORCID 0000-0002-9419-6387, UCLouvain/University of Antwerp) as the primary author record with 410 works, 17,342 citations, and h-index 65; a second, sparser record (Y. Glupczynski, h-index 5, 31 works) reflects name-form fragmentation, so the larger profile is the credible estimate. Citation density peaked in 2012 (2,492 citations; 22 works) and 2016 (1,857 citations; 19 works), with continuing output through 2024–2026, indicating a career spanning four decades.

His highest-impact work includes a landmark aminoglycoside activity/resistance review (1,113 citations, cited count per OpenAlex) Aminoglycoside activity and resistance review, the European carbapenemase evolution review European carbapenemase evolution review, and two Gut studies linking European H. pylori clarithromycin/levofloxacin resistance to community antibiotic consumption (840 and 296 citations) H. pylori resistance vs antibiotic consumption in Europe H. pylori resistance 2018 European update. He also co-authored a Nature Microbiology genomic-epidemiology study on nosocomial spread of carbapenem-resistant K. pneumoniae (777 citations) and the EuSCAPE multinational survey (664 citations) Genomic epidemiology of CRKP in Europe EuSCAPE multinational CPE survey.

Scientific Strength of the Reviewed Study

The diagnostic evaluation of the ESBL-Bx chromogenic agar demonstrates applied clinical-microbiology competence: a prospective head-to-head comparison on 644 clinical specimens (551 fecal) from 460 hospitalized patients, showing ESBL-Bx was more sensitive than the homemade ceftazidime-supplemented MacConkey medium and permitted presumptive identification within 24 h ESBL-Bx chromogenic agar evaluation. Rigor is qualified by author-reported blind spots: selective specimen origin/ward sampling limits prevalence inference, the ESBL-Bx supplement composition was undisclosed (reproducibility concern), and no clinical-outcome data were collected. The false-positive analysis is informative—AmpC-hyperproducing Enterobacter spp. (n=14) dominated, and 44 non-Enterobacteriaceae isolates (mainly P. aeruginosa n=30, S. maltophilia n=12) grew on 37 specimens.

Confidence and caveats: Metrics derive from OpenAlex, which can inflate co-authorship attribution in large consortia; the detailed evidence record covers only one paper. His career-long role appears to be a respected expert contributor (EU CPE networks, H. pylori surveillance) rather than a singular paradigm-shifting investigator. Evidence that would change this assessment: first-authored high-impact methodological or mechanistic papers beyond the 1999 aminoglycoside review.

 BGPT Author Review

Scientific Quality

h-index 65 with 17,342 citations and 410 works indicates sustained, high-level contribution to clinical microbiology and resistance epidemiology. Most landmark outputs are co-authored consortium papers (EuSCAPE, Nature Microbiology genomic epidemiology), so individual scientific leadership is harder to isolate; the ESBL-Bx study shows solid applied diagnostic rigor but moderate reproducibility (undisclosed supplement composition).

Communication Quality

Papers are published in top-tier clinical microbiology venues with clear comparative designs and transparent author-reported limitations (sampling bias, undisclosed reagent composition), but much output is French-language review material and consortium formats limit individual narrative voice.

Author Novelty

Work largely applies and surveys established methods (chromogenic agars, susceptibility surveillance, genomic epidemiology) rather than introducing new paradigms; the early H. pylori and aminoglycoside reviews were field-defining syntheses at their time.

Scientific Rigor

The ESBL-Bx evaluation is prospective, specimen-level, and transparently reports false positives and its own limitations; however, it lacks statistical testing detail, has selective sampling, undisclosed reagent composition, and no clinical outcomes, capping rigor assessment.